{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T17:16:15Z","timestamp":1784740575084,"version":"3.55.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T00:00:00Z","timestamp":1591833600000},"content-version":"am","delay-in-days":376,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","trasci.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.transci.2019.04.012","type":"journal-article","created":{"date-parts":[[2019,4,19]],"date-time":"2019-04-19T11:06:41Z","timestamp":1555672001000},"page":"273-277","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["When targeted therapies alleviate the burden of TPE: The example of immune-mediated TTP"],"prefix":"10.1016","volume":"58","author":[{"given":"Adrien","family":"Picod","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Coppo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"April (3)","key":"10.1016\/j.transci.2019.04.012_bib0005","first-page":"17021","article-title":"Thrombotic thrombocytopenic purpura","volume":"6","author":"Kremer Hovinga","year":"2017","journal-title":"Nat Rev Dis Prim"},{"issue":"May (21)","key":"10.1016\/j.transci.2019.04.012_bib0010","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1182\/blood-2016-10-709857","article-title":"Thrombotic thrombocytopenic purpura","volume":"129","author":"Joly","year":"2017","journal-title":"Blood"},{"issue":"April (1)","key":"10.1016\/j.transci.2019.04.012_bib0015","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/jca.20091","article-title":"Rituximab therapy for thrombotic thrombocytopenic purpura: a proposed study of the Transfusion Medicine\/Hemostasis Clinical Trials Network with a systematic review of rituximab therapy for immune-mediated disorders","volume":"21","author":"George","year":"2006","journal-title":"J Clin Apheresis"},{"issue":"August (7)","key":"10.1016\/j.transci.2019.04.012_bib0020","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1182\/blood-2011-03-341131","article-title":"A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura","volume":"118","author":"Scully","year":"2011","journal-title":"Blood"},{"issue":"March (3)","key":"10.1016\/j.transci.2019.04.012_bib0025","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/jth.12114","article-title":"Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse","volume":"11","author":"Westwood","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"June (6428)","key":"10.1016\/j.transci.2019.04.012_bib0030","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/363446a0","article-title":"Naturally occurring antibodies devoid of light chains","volume":"363","author":"Hamers-Casterman","year":"1993","journal-title":"Nature"},{"issue":"October (17)","key":"10.1016\/j.transci.2019.04.012_bib0035","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1182\/blood-2012-04-420943","article-title":"Evaluation of efficacy and safety of the anti-VWF nanobody ALX-0681 in a preclinical baboon model of acquired thrombotic thrombocytopenic purpura","volume":"120","author":"Callewaert","year":"2012","journal-title":"Blood"},{"issue":"February (6)","key":"10.1016\/j.transci.2019.04.012_bib0040","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1505533","article-title":"Caplacizumab for acquired thrombotic thrombocytopenic Purpura","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N Engl J Med"},{"issue":"January 9","key":"10.1016\/j.transci.2019.04.012_bib0045","article-title":"Caplacizumab treatment for acquired thrombotic thrombocytopenic Purpura","author":"Scully","year":"2019","journal-title":"N Engl J Med"},{"issue":"November (19)","key":"10.1016\/j.transci.2019.04.012_bib0050","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/blood-2017-06-788026","article-title":"Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura","volume":"130","author":"Scully","year":"2017","journal-title":"Blood"},{"issue":"May (5)","key":"10.1016\/j.transci.2019.04.012_bib0055","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/j.1538-7836.2011.04224.x","article-title":"Recombinant ADAMTS13 normalizes von Willebrand factor-cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies: rADAMTS13 overrides inhibitors in TTP plasma","volume":"9","author":"Plaimauer","year":"2011","journal-title":"J Thromb Haemost"},{"issue":"July (1)","key":"10.1016\/j.transci.2019.04.012_bib0060","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1001\/archinte.1925.00120130092009","article-title":"An acute febrile pleiochromic anemia with hyaline thrombosis of the terminal arterioles and capillaries: an unde- scribed disease","volume":"36","author":"Moschcowitz","year":"1925","journal-title":"Arch Intern Med"},{"issue":"November (22)","key":"10.1016\/j.transci.2019.04.012_bib0065","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1056\/NEJM199811263392202","article-title":"Von willebrand factor\u2013Cleaving protease in thrombotic thrombocytopenic Purpura and the hemolytic\u2013Uremic syndrome","volume":"339","author":"Furlan","year":"1998","journal-title":"N Engl J Med"},{"issue":"November (22)","key":"10.1016\/j.transci.2019.04.012_bib0070","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1056\/NEJM199811263392203","article-title":"Antibodies to von willebrand factor\u2013Cleaving protease in acute thrombotic thrombocytopenic Purpura","volume":"339","author":"Tsai","year":"1998","journal-title":"N Engl J Med"},{"issue":"December (25)","key":"10.1016\/j.transci.2019.04.012_bib0075","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1056\/NEJM197712222972507","article-title":"Treatment of thrombotic thrombocytopenic Purpura with plasma","volume":"297","author":"Byrnes","year":"1977","journal-title":"N Engl J Med"},{"issue":"August (6)","key":"10.1016\/j.transci.2019.04.012_bib0080","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJM199108083250604","article-title":"Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic Purpura","volume":"325","author":"Rock","year":"1991","journal-title":"N Engl J Med"},{"issue":"June (2)","key":"10.1016\/j.transci.2019.04.012_bib0085","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1365-2141.1994.tb04915.x","article-title":"The treatment of thrombotic thrombocytopenic purpura: plasma infusion or exchange?","volume":"87","author":"Novitzky","year":"1994","journal-title":"Br J Haematol"},{"issue":"January (1)","key":"10.1016\/j.transci.2019.04.012_bib0090","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/00005792-200301000-00003","article-title":"High-dose plasma infusion versus plasma exchange as early treatment of thrombotic thrombocytopenic purpura\/hemolytic-uremic syndrome","volume":"82","author":"Coppo","year":"2003","journal-title":"Medicine (Baltimore)"},{"issue":"June (6)","key":"10.1016\/j.transci.2019.04.012_bib0095","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/BF01696619","article-title":"Thrombotic thrombocytopenic purpura\/hemolytic uremic syndrome: a multivariate analysis of factors predicting the response to plasma exchange","volume":"70","author":"Pereira","year":"1995","journal-title":"Ann Hematol"},{"issue":"December (6)","key":"10.1016\/j.transci.2019.04.012_bib0100","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/jca.21288","article-title":"The use of 50% albumin\/plasma replacement fluid in therapeutic plasma exchange for thrombotic thrombocytopenic purpura: fifty Percent Albumin\/Plasma Fluid for TPE in TTP","volume":"28","author":"O\u2019Brien","year":"2013","journal-title":"J Clin Apheresis"},{"issue":"May (4)","key":"10.1016\/j.transci.2019.04.012_bib0105","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/j.1423-0410.2011.01562.x","article-title":"Evaluation of the hemostatic potential including thrombin generation of three different therapeutic pathogen-reduced plasmas: hemostatic potential of therapeutic plasma","volume":"102","author":"Hacquard","year":"2012","journal-title":"Vox Sang"},{"issue":"May (4)","key":"10.1016\/j.transci.2019.04.012_bib0110","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.0042-9007.2004.00506.x","article-title":"Methylene blue-photoinactivated plasma vs. Fresh-frozen plasma as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura","volume":"86","author":"Alvarez-Larran","year":"2004","journal-title":"Vox Sang"},{"issue":"October (1)","key":"10.1016\/j.transci.2019.04.012_bib0115","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1365-2141.2008.07292.x","article-title":"Methylene blue-photoinactivated plasma versus quarantine fresh frozen plasma in thrombotic thrombocytopenic purpura: a multicentric, prospective cohort study","volume":"143","author":"del R\u00edo-Garma","year":"2008","journal-title":"Br J Haematol"},{"issue":"September (3","key":"10.1016\/j.transci.2019.04.012_bib0120","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1046\/j.1365-2141.2001.02991.x","article-title":"Role of methylene blue-treated or fresh-frozen plasma in the response to plasma exchange in patients with thrombotic thrombocytopenic purpura","volume":"114","author":"de la Rubia","year":"2001","journal-title":"Br J Haematol"},{"issue":"August (2)","key":"10.1016\/j.transci.2019.04.012_bib0125","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/ejh.12706","article-title":"Twice-daily therapeutical plasma exchange-based salvage therapy in severe autoimmune thrombotic thrombocytopenic purpura: the French TMA Reference Center experience","volume":"97","author":"Soucemarianadin","year":"2016","journal-title":"Eur J Haematol"},{"issue":"November (2)","key":"10.1016\/j.transci.2019.04.012_bib0130","first-page":"349","article-title":"Twice-daily plasma exchange for patients with refractory thrombotic thrombocytopenic purpura: the experience of the Oklahoma Registry, 1989 through 2006","volume":"48","author":"Nguyen","year":"2007","journal-title":"Transfusion (Paris)"},{"issue":"February (2)","key":"10.1016\/j.transci.2019.04.012_bib0135","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/jth.13571","article-title":"Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies","volume":"15","author":"Scully","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"August (4)","key":"10.1016\/j.transci.2019.04.012_bib0140","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1182\/blood-2004-11-4490","article-title":"ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases","volume":"106","author":"Rieger","year":"2005","journal-title":"Blood"},{"issue":"December 12","key":"10.1016\/j.transci.2019.04.012_bib0145","article-title":"Prognostic value of anti-ADAMTS13 antibodies features (Ig isotype, titer and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with an undetectable ADAMTS13 activity","author":"Ferrari","year":"2006","journal-title":"Blood"},{"issue":"February (1)","key":"10.1016\/j.transci.2019.04.012_bib0150","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jca.21257","article-title":"Therapeutic plasma exchange: a technical and operational review: therapeutic Plasma Exchange","volume":"28","author":"Kaplan","year":"2013","journal-title":"J Clin Apheresis"},{"issue":"01","key":"10.1016\/j.transci.2019.04.012_bib0155","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1055\/s-0037-1614408","article-title":"Recovery and Half-Life of Von Willebrand factor-cleaving protease after plasma therapy in patients with thrombotic thrombocytopenic Purpura","volume":"81","author":"Furlan","year":"1999","journal-title":"Thromb Haemost"},{"issue":"June (11)","key":"10.1016\/j.transci.2019.04.012_bib0160","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1182\/blood-2003-11-4035","article-title":"Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura","volume":"103","author":"Zheng","year":"2004","journal-title":"Blood"},{"issue":"June (6)","key":"10.1016\/j.transci.2019.04.012_bib0165","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1111\/j.1538-7836.2006.01960.x","article-title":"Patterns of changes of anti-ADAMTS13 after plasma exchange","volume":"4","author":"Mannucci","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"June (6)","key":"10.1016\/j.transci.2019.04.012_bib0170","first-page":"591","article-title":"High versus standard dose methylprednisolone in the acute phase of idiopathic thrombotic thrombocytopenic purpura: a randomized study","volume":"89","author":"Italian","year":"2010","journal-title":"Ann Hematol"},{"issue":"February (1)","key":"10.1016\/j.transci.2019.04.012_bib0175","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood-2008-02-078170","article-title":"Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura","volume":"112","author":"Sadler","year":"2008","journal-title":"Blood"},{"issue":"January (1)","key":"10.1016\/j.transci.2019.04.012_bib0180","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/CCM.0b013e31822e9d66","article-title":"Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center","volume":"40","author":"Froissart","year":"2012","journal-title":"Crit Care Med"},{"issue":"July (4)","key":"10.1016\/j.transci.2019.04.012_bib0185","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1179\/1607845412Y.0000000073","article-title":"Low-dose rituximab for the treatment of acute thrombotic thrombocytopenic purpura: report of four cases","volume":"18","author":"Peque\u00f1o-Lu\u00e9vano","year":"2013","journal-title":"Hematology"},{"issue":"May (5)","key":"10.1016\/j.transci.2019.04.012_bib0190","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/10245332.2015.1133008","article-title":"More about low-dose rituximab and plasma exchange as front-line therapy for patients with thrombotic thrombocytopenic purpura","volume":"21","author":"Vazquez-Mellado","year":"2016","journal-title":"Hematology"},{"issue":"December (12)","key":"10.1016\/j.transci.2019.04.012_bib0195","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1002\/ajh.24559","article-title":"Efficacy of a rituximab regimen based on B cell depletion in thrombotic thrombocytopenic purpura with suboptimal response to standard treatment: results of a phase II, multicenter noncomparative study: B cell driven rituximab therapy in TTP","volume":"91","author":"Benhamou","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.transci.2019.04.012_bib0200","article-title":"Efficacy of adjuvant low dose rituximab and plasma exchange for acquired TTP with severe ADAMTS13 deficiency \u2013 results of the ART study","author":"Zwicker","year":"2018","journal-title":"In ASH"},{"issue":"June (5)","key":"10.1016\/j.transci.2019.04.012_bib0205","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/bjh.13993","article-title":"Bortezomib in the treatment of refractory thrombotic thrombocytopenic purpura","volume":"173","author":"Patriquin","year":"2016","journal-title":"Br J Haematol"},{"issue":"November (1)","key":"10.1016\/j.transci.2019.04.012_bib0210","first-page":"26","article-title":"Thrombotic thrombocytopenic purpura: Toward targeted therapy and precision medicine","volume":"3","author":"Coppo","year":"2018","journal-title":"Res Pract Thromb Haemost"}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050219300618?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050219300618?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T08:49:17Z","timestamp":1761468557000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473050219300618"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S1473050219300618"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2019.04.012","relation":{},"ISSN":["1473-0502"],"issn-type":[{"value":"1473-0502","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"When targeted therapies alleviate the burden of TPE: The example of immune-mediated TTP","name":"articletitle","label":"Article Title"},{"value":"Transfusion and Apheresis Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transci.2019.04.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}